EGLN2 and breast cancer: On the other hand, a reduction in PHD1 levels in breast cancer can hinder tumor growth due to the accumulation of FOXO3a and consequent suppression of cyclin D1 eventually leading to a decreased proliferation (Zhang et al, 2009; Zheng et al, 2014).